Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Maio(University of Siena), Brigitte Dréno(Nantes Université), A. Mackiewicz, Delphine Hennicken(Inova Fairfax Hospital), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Catriona M. McNeil(Chris O’Brien Lifehouse), Lars Bastholt(Odense University Hospital), Henrik Schmidt(University of Southern Denmark), Jean‐Jacques Grob(Aix-Marseille Université), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Carmen Loquai(Johannes Gutenberg University Mainz), L. Thomas(University of Liverpool), Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anila Qureshi(Bristol-Myers Squibb (United States)), Claus Garbe(University of Tübingen)
Cited by 23
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k